Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualised neoantigen cancer vaccine therapy.

Lancet (London, England) - 17 Feb 2024

Terai Mizue, Sato Takami

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Immunotherapy
Share to Mutation
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38246193
DOI: 10.1016/S0140-6736(23)02463-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualised neoantigen cancer vaccine therapy.PMID 38246193Read ↗

Identification of neoantigens for individualized therapeutic cancer vaccinesSemantic proximity Read ↗

Developing neoantigen-targeted T cell–based treatments for solid tumorsSemantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?Semantic proximity Read ↗

Advances in personalized neoantigen vaccines for cancer immunotherapy.Semantic proximity Read ↗

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapySemantic proximity Read ↗

Personalized Neoantigen DNA Cancer Vaccines: Current Status and Future PerspectivesSemantic proximity Read ↗

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Semantic proximity Read ↗

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read ↗

An immunogenic personal neoantigen vaccine for patients with melanoma.Semantic proximity Read ↗

Cancer Neoantigen Vaccines Emerge Efficacious.Semantic proximity Read ↗

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.